INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

计划入组 90 人 · 首次发布于 2021 年 3 月 4 日

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

计划入组 380 人 · 首次发布于 2025 年 2 月 14 日

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

计划入组 61 人 · 首次发布于 2024 年 4 月 10 日

iNTS2 Vaccine

Amgen Settles Denosumab Biosimilar Patent Dispute with Accord BioPharma

Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC

Intensity Therapeutics Initiates Phase 3 Trial of INT230-6 for Metastatic Sarcoma